51
|
Alvarez Alija G, Menéndez S, García-Carracedo D, Allonca E, Mancebo G, Suárez C, Rodrigo J, García-Pedrero J. 155 Clinical significance of the expression and amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70963-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
52
|
Aparicio V, Gil P, Juárez A, Suárez C. Síndrome de Sweet con afectación pulmonar de evolución fatal. Rev Clin Esp 2010. [DOI: 10.1016/j.rce.2010.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
53
|
Olaiz N, Suárez C, Risk M, Molina F, Marshall G. Tracking protein electrodenaturation fronts in the electrochemical treatment of tumors. Electrochem commun 2010. [DOI: 10.1016/j.elecom.2009.10.044] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
54
|
Serrano C, Suárez C, Andreu J, Carles J. Acute aortic dissection during sorafenib-containing therapy. Ann Oncol 2010; 21:181-2. [DOI: 10.1093/annonc/mdp468] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
55
|
Turjanski P, Olaiz N, Abou-Adal P, Suárez C, Risk M, Marshall G. pH front tracking in the electrochemical treatment (EChT) of tumors: Experiments and simulations. Electrochim Acta 2009. [DOI: 10.1016/j.electacta.2009.05.062] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
56
|
Suárez C. Preparation of Carrier-free 35SH2 Through Direct Reduction of the 35SO4
- Contained in Neutron Irradiated KCl. RADIOCHIM ACTA 2009. [DOI: 10.1524/ract.1966.6.3.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
57
|
Guix M, Lema L, Lloreta J, Rojo F, Suárez C, Carles J, de la Cruz J, Sánchez-Carbayo M, Albanell J, Bellmunt J. Excision repair cross-complementing 1 (ERCC1) and survival in advanced bladder cancer: Confirmatory results using immunohistochemistry. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5025] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5025 Background: DNA damaging agents are the backbone of combination chemotherapy regimens for the treatment of advanced bladder cancer. We hypothesized that levels of DNA repair genes such as ERCC1 could predict survival in patients receiving platinum based therapy. Our previous work (Bellmunt J et al, Ann Oncol. 2007) showed that survival was significantly higher in advanced bladder cancer patients with low gene expression levels of ERCC1 measured by RT-qPCR (25.4 versus 15.4 months; p = 0.03). We aimed to confirm these findings using immunohistochemistry (IHC) in an independent cohort of advanced bladder cancer patients treated with cisplatin-based chemotherapy at our institution. Methods: Formalin-fixed paraffin-embedded tumor tissue was available from 51 patients. IHC stains for ERCC1 protein levels were scored as percentage and intensity of positive cells. ERCC1 staining was considered positive if detected in ≥1% tumor cells. The Kaplan-Meier method was used to calculate survival and the Cox proportional hazards model was used to examine the prognostic value of protein expression levels. Results: ERCC1 staining was negative in 60% of patients, weakly positive (1–10% positive cells) in 21% and strongly positive (>10% positive cells) in 19%. Median overall survival for all patients was 14.4m (95% CI 6.7–16.1m). Median disease-specific survival was significantly higher in patients negative for ERCC1 by IHC (12.6m versus 8.6m; p = 0.032). Conclusions: Our results using the more simple IHC technique confirm the prognostic value of ERCC1 expression in advanced bladder cancer. Patients with high expression of ERCC1 by IHC have a worse disease-specific survival than patients with no expression. A correlative study of IHC and RT-qPCR in both sets of samples is ongoing. No significant financial relationships to disclose.
Collapse
|
58
|
Gómez-Cía T, Gacto-Sánchez P, Sicilia D, Suárez C, Acha B, Serrano C, Parra C, De La Higuera J. The virtual reality tool VirSSPA in planning DIEP microsurgical breast reconstruction. Int J Comput Assist Radiol Surg 2009; 4:375-82. [DOI: 10.1007/s11548-009-0311-4] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2009] [Accepted: 04/14/2009] [Indexed: 12/27/2022]
|
59
|
Suárez C, Ruiz-Giménez N. Anticoagulación preventiva: ejemplo de análisis de riesgo/beneficio. REVISTA CLÍNICA ESPAÑOLA 2009; 209:157-9. [DOI: 10.1016/s0014-2565(09)71307-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
60
|
Rodrigo JP, García-Carracedo D, García LA, Menéndez S, Allonca E, González MV, Fresno MF, Suárez C, García-Pedrero JM. Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas. J Pathol 2009; 217:516-23. [PMID: 18991334 DOI: 10.1002/path.2462] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Amplification of the 11q13 region is a prevalent genetic alteration in head and neck squamous cell carcinoma (HNSCC). We investigated the clinical significance of cortactin (CTTN) and cyclin D1 (CCND1) amplification in both malignant transformation and tumour progression. CTTN and CCND1 amplification was analysed by differential and real-time PCR in a prospective series of laryngeal/pharyngeal carcinomas and archival premalignant tissues. CTTN mRNA and protein expression were respectively determined by real-time RT-PCR and immunohistochemistry, and correlated with gene status. Molecular alterations were associated with clinicopathological parameters and disease outcome. CTTN and CCND1 amplifications were respectively found in 75 (37%) and 90 (45%) tumours. Both correlated with advanced disease; however, only CTTN amplification was associated with recurrence and reduced disease-specific survival (p = 0.0022). Strikingly, CTTN amplification differentially influenced survival depending on tumour site (p = 0.0001 larynx versus p = 0.68 pharynx) and was an independent predictor of reduced survival in the larynx (p = 0.04). CCND1 amplification was detected in early tumourigenesis and increased with the severity of dysplasia. Importantly, CTTN amplification was only found in high-grade dysplasias that progressed to invasive carcinoma. CTTN gene status strongly correlated with mRNA and protein expression. Furthermore, CTTN overexpression correlated significantly with reduced disease-specific survival (p = 0.018). Taken together, these data indicate that CTTN may serve as a valuable biomarker to identify patients with laryngeal tumours at high risk of recurrence and poor outcome.
Collapse
|
61
|
Bellmunt J, Albiol S, Suárez C, Albanell J. Optimizing therapeutic strategies in advanced bladder cancer: Update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hematol 2009; 69:211-22. [DOI: 10.1016/j.critrevonc.2008.06.002] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2008] [Revised: 05/30/2008] [Accepted: 06/05/2008] [Indexed: 11/25/2022] Open
|
62
|
Suárez C, Acha B, Serrano C, Parra C, Gómez T. VirSSPA- A virtual reality tool for surgical planning workflow. Int J Comput Assist Radiol Surg 2009; 4:133-9. [DOI: 10.1007/s11548-009-0284-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2008] [Accepted: 12/29/2008] [Indexed: 10/21/2022]
|
63
|
Suárez C, Manzano L, Mostaza J, Cairols M, Palma JC, García I, Acosta A, Diodado F, Comas L, Marco JM. [Prevalence of peripheral artery disease evaluated by ankle brachial index in patients with metabolic syndrome. MERITO I study]. Rev Clin Esp 2007; 207:228-33. [PMID: 17504666 DOI: 10.1157/13102314] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
INTRODUCTION Patients with Metabolic Syndrome have high cardiovascular morbidity and mortality rate above that expected when using accepted scales for risk stratification. Ankle brachial index (ABI) is an available, straightforward and reproducible method for the detection of peripheral vascular disease and for improving risk stratification in this population. Our study aimed to evaluate the prevalence of low ABI in patients with metabolic syndrome older than 50 years and to study the risk factors associated with its development. PATIENTS AND METHODS 1519 subjects between 50 and 85 years, 935 of them with metabolic syndrome (Adult Treatment Panel III [ATP III] criteria), in primary prevention, without symptoms of intermittent claudication and who gave their consent to have an ABI measurement in internal medicine offices were included in the study. Cardiovascular risk factors were evaluated in all participants. An ABI < 0.9 was considered low. RESULTS The prevalence of a low ABI in subjects with metabolic syndrome was 27.7 (95% CI: 24.8-30.5). Factors associated with low and a pathological ABI were age, higher serum creatinine levels and presence of proteinuria. After multivariate adjustment, only age (OR: 1.07; 95% CI: 1.04-1.09) and active tobacco use (OR: 1.45; 95% CI: 1.10-1.92) continued to be significant. CONCLUSION Prevalence of a low ABI is elevated in subjects with metabolic syndrome without known cardiovascular disease and related with age and active tobacco use.
Collapse
|
64
|
Viloria CG, Peinado JR, Astudillo A, García-Suárez O, González MV, Suárez C, Cal S. Human DESC1 serine protease confers tumorigenic properties to MDCK cells and it is upregulated in tumours of different origin. Br J Cancer 2007; 97:201-9. [PMID: 17579619 PMCID: PMC2360300 DOI: 10.1038/sj.bjc.6603856] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Proteolysis of the extracellular matrix components plays a crucial role in the regulation of the cellular and physiological processes, and different pathologies have been associated with the loss or gain of function of proteolytic enzymes. DESC1 (differentially expressed in squamous cell carcinoma gene 1), a member of the TTSP (type II transmembrane serine protease) family of serine proteases, is an epithelial-specific enzyme that has been found downregulated in squamous cell carcinoma of the head and neck region. We describe new properties of DESC1 suggesting that this protease may be involved in the progression of some type of tumours. Thus, this enzyme hydrolyses some extracellular matrix components, such as fibronectin, gelatin or fibrinogen. Moreover, Madin–Darby canine kidney (MDCK) cells expressing exogenous human DESC1 acquire properties associated with tumour growth such as enhanced motility and an increase of tubular forms in a 3D collagen lattice following HGF treatment. Finally, we generated polyclonal anti-DESC1 antibodies and immunohistochemical analysis in tissues different from head and neck region indicated that this protease was overexpressed in tumours of diverse origins. Taken together, our results suggest that DESC1 could be considered as a potential therapeutic target in some type of tumours.
Collapse
|
65
|
Fernández JA, Suárez C, Navarro A, Díaz C, Alvarez JC, González del Rey C, Tolivia J. Aging in the vestibular nuclear complex of the male golden hamster (Mesocricetus auratus): anatomic and morphometric study. Histol Histopathol 2007; 22:855-68. [PMID: 17503342 DOI: 10.14670/hh-22.855] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
To study the effects of senescence on the vestibular nuclear complex twenty brainstems from male golden hamsters between 3 and 27 months-old were used and the possible variations in the number of neurons, neuronal morphology and nuclear volume were studied. The neuron profiles were drawn with a camera lucida and Abercrombie's method was used to estimate the total number of neurons. The test of Kolmogorov-Smirnov with the correction of Lilliefors was used to evaluate the fit of our data to a normal distribution and a regression analysis was done to decide if the variation of our data with age was statistically significant. The results of the present study are relevant only for male animals and the effect of senescence could be different in female vestibular nuclear complex. Aging affects the volume of the superior and lateral vestibular nuclei, as well as the nuclear neuronal diameter of the medial vestibular nucleus, but no significant neuronal loss has been appreciated in vestibular nuclear complex related with age. During the aging process we have observed that the distribution of neurons within the vestibular nuclei of the golden hamster does not show important changes and most of their morphometric parameters do not vary significantly.
Collapse
|
66
|
Coca A, Bertomeu V, Dalfó A, Esmatjes E, Guillén F, Guerrero L, Llisterri JL, Marín-Iranzo R, Megía C, Rodríguez-Mañas L, Suárez C. Automedida de la presión arterial. Documento de Consenso Español 2007. Rev Clin Esp 2007; 207:197-208. [PMID: 17475185 DOI: 10.1157/13101851] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
67
|
Coca A, Bertomeu V, Dalfó A, Esmatjes E, Guillén F, Guerrero L, Llisterri J, Marín-Iranzo R, Megía C, Rodríguez-Mañas L, Suárez C. Automedida de la presión arterial. Documento de Consenso Español 2007. Semergen 2007. [DOI: 10.1016/s1138-3593(07)73873-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
68
|
Benítez M, González Gómez I, González Carmelo I, Palma A, Cruz S, Rodríguez E, Amián A, Fernández M F, Merino MJ, Fernández G F, Suárez C, Onaindía JM, González J. [Heparin immune thrombocytopenia in a hemodialysis patient. A case report. Literature review]. Nefrologia 2007; 27:756-760. [PMID: 18336108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023] Open
Abstract
Heparin-induced thrombocytopenia (HIT) is an important side effect of heparin therapy associated with significant morbidity and mortality if unrecognized. The platelet count typically falls below 150,000/ll 5-14 days after heparin is started. Thrombosis is the major clinical complication. We present the case gives a patient that develops a deep vein thrombosis ilio-femoral left, with trombocytopenia, one week after beginning treatment with haemodialysis in which Ac anti heparin is detected by test PaGIA (Particle Gel Inmuno Assay.
Collapse
|
69
|
Coca A, Bertomeu V, Dalfó A, Esmatjes E, Guillén F, Guerrero L, Llisterri JL, Marín-Iranzo R, Megía C, Rodríguez-Mañas L, Suárez C. [Blood pressure self measurement: Spanish consensus document]. Nefrologia 2007; 27:139-53. [PMID: 17564558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/15/2023] Open
|
70
|
Coca A, Bertomeu V, Dalfó A, Esmatjes E, Guillén F, Guerrero L, Llisterri J, Marín-Iranzo R, Megía C, Rodríguez-Mañas L, Suárez C. Automedida de la presión arterial. Documento de Consenso Español 2007. HIPERTENSION Y RIESGO VASCULAR 2007. [DOI: 10.1016/s1889-1837(07)71682-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
71
|
Carreño M, Llorente JL, Suárez C. Vestibular schwannoma: unusual recurrence presenting as an external auditory canal mass. Skull Base Surg 2006; 9:141-3. [PMID: 17171129 PMCID: PMC1656799 DOI: 10.1055/s-2008-1058160] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Vestibular schwannomas (VS) commonly are limited to the internal auditory canal (IAC) and cerebellopontine angle. Extension to labyrinth is less frequent, and involvement of the middle ear or external acoustic canal (EAC) is very rare. In this report we present the case of a 41-year-old woman with a VS, which recurred after a previous surgical removal 4 years before. The tumor involved the IAC, cochlea, vestibule, semicircular canals, cavum tympani, mastoid cells, and EAC. Total removal of the tumor was achieved by a transotic approach, without neurological sequela.
Collapse
|
72
|
Coca A, Aranda P, Bertomeu V, Bonet A, Esmatjes E, Guillén F, Hernández-Moreno J, Llisterri JL, Marín-Iranzo R, Megía C, Rodríguez-Mañas L, Suárez C. Estrategias para un control eficaz de la hipertensión arterial en España. Documento de consenso. Rev Clin Esp 2006; 206:510-4. [PMID: 17129520 DOI: 10.1157/13094902] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Blood pressure (BP) control is inadequate among treated hypertensive patients in Spain. Control rates are lower than 40% of all treated patients and the cause of this problem is multifactorial. Despite the fact that possible solutions to this problem have been repeatedly suggested by expert groups along the last 10 years, BP control rates are still low. This fact have a negative impact on cardiovascular morbidity and mortality of patients with hypertension. The aim of the present document has been to achieve a consensus on effective specific measures in order to improve hypertension control rates in Spain. These measures involve health care professionals (physicians, nurses, pharmaceutics), health care authorities and patients. The document summarizes the consensus conference of several scientific societies involved in cardiovascular medicine in five group of measures: a) improvement of the methodology of office BP measurement; b) improvement of compliance to treatment by patients; c) clarification of pressure targets to be achieved in hypertensive patients; d) optimization of life style modifications and pharmacological treatment of hypertension; and e) continuous medical education. The document emphasize life style changes as a crucial aspect to be implemented in all patients. These changes have a beneficial impact on pressure reduction, contribute to a better control of associated cardiovascular risk factors, and increase the effectiveness of antihypertensive drugs. Health care professionals should base their clinical practice on the recommendations of guidelines in order to modify their therapeutic attitudes in patients whose targets have not been achieved.
Collapse
|
73
|
Moscoso J, Rudolph A, Sepúlveda RD, Suárez C. Effect of temporary closure of the mouth of an estuary on the benthic macroinfauna: Lenga-Chile, a case study. BULLETIN OF ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY 2006; 77:484-91. [PMID: 17123006 DOI: 10.1007/s00128-006-1090-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/17/2005] [Accepted: 09/26/2006] [Indexed: 05/12/2023]
|
74
|
Monreal M, Falgá C, Valdés M, Suárez C, Gabriel F, Tolosa C, Montes J. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006; 4:1950-6. [PMID: 16961602 DOI: 10.1111/j.1538-7836.2006.02082.x] [Citation(s) in RCA: 155] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVES To examine the clinical characteristics and outcomes of cancer patients with venous thromboembolism (VTE) in order to identify factors that place these patients at an increased risk for fatal pulmonary embolism (PE) or fatal bleeding. PATIENTS AND METHODS Registro Informatizado de la Enfermedad Trombo Embólica (RIETE) is a prospective registry of consecutive patients with symptomatic, objectively confirmed, acute VTE. RESULTS Up to January 2006, a total of 14 391 patients with symptomatic acute VTE were enrolled in RIETE, of whom 2945 (20%) had cancer. During the 3-month follow-up period the frequency of fatal PE in cancer patients was 2.6%, and that of fatal bleeding 1.0%. These frequencies were significantly higher than in VTE patients without cancer (1.4% and 0.3%, respectively). In patients with cancer, abnormal renal function, metastatic disease, recent major bleeding and recent immobility for >or= 4 days (42% of the 108 patients who died from PE or bleeding had recent immobility) were factors independently associated with an increased risk for both fatal PE and fatal bleeding. In addition, PE diagnosis on admission was an independent risk factor for fatal PE, while body weight < 60 kg was an independent risk factor for fatal bleeding. CONCLUSIONS Both fatal PE and fatal bleeding are more common in cancer patients with VTE than in those patients without cancer. In cancer patients, abnormal renal function, metastatic disease, recent major bleeding and recent immobility for >or= 4 days are associated with an increased risk for both fatal PE and fatal bleeding.
Collapse
|
75
|
Coca A, Aranda P, Bertomeu V, Bonet A, Esmatjes E, Guillén F, Hernández-Moreno J, Llisterri J, Marín-Iranzo R, Megía C, Rodríguez-Mañas L, Suárez C. Estrategias para un control eficaz de la hipertensión arterial en España. Documento de Consenso. Semergen 2006. [DOI: 10.1016/s1138-3593(06)73284-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|